Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.45 |
| ▸ | FAP | Q12884 | 14/20 | 0.45 |
| ▸ | PREP | P48147 | 6/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 13/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.42 |
| ▸ | PITRM1 | Q5JRX3 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13452587 | 0.86 | DPP4 (0.46) | DPP4FAPPREPDPP7DPP9 | |
| SCHEMBL8288245 | 0.84 | EPHX2 (0.39) | DPP4FAPPREP | |
| SCHEMBL13372095 | 0.76 | PREP (0.37) | DPP4FAPPREPDPP7DPP9 | |
| SCHEMBL13371993 | 0.75 | KMT2A (0.47) | — | |
| SCHEMBL13347235 | 0.75 | DPP4 (0.64) | DPP4FAPPREPDPP7DPP9 | |
| SCHEMBL8214962 | 0.75 | DPP4 (0.45) | DPP4FAPPREPDPP7DPP9 | |
| SCHEMBL13452746 | 0.71 | POLB (0.41) | DPP4FAPPREPDPP7DPP9 | |
| SCHEMBL15335279 | 0.65 | FAP (0.63) | DPP4FAPPREPDPP7DPP9 | |
| SCHEMBL8250531 | 0.62 | FAP (1.00) | DPP4FAPPREPDPP7DPP9 | |
| SCHEMBL20811835 | 0.61 | MAPK1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415295-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1997533-A1 | Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors | Phenomix Corporation (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20070185061-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | PHENOMIX CORPORATION | 2007-08-09 | — | — | US | disclosed |
| EP-1743676-A1 | Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors | Phenomix Corporation (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005047297-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185061-A1 | (2R)-1-{2-[(3R)-pyrrolidin-3-ylamino]-acetyl}-pyrrolidine-2-boronic acid; Dipeptidyl peptidase IV (DPP-IV) inhibitors; diabetes, hyperglycemia, Syndrome X, hyperinsulinemia, obesity, atherosclerosis | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 209/4885PREP 87/4885 |
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 238/4885PREP 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.